본문 바로가기
KERD
논문KCI 등재

Association between BRAFV600E Mutations and Clinicopathological Features of Papillary Thyroid Microcarcinoma (PTMC)

2

조회

0

다운로드

1

인용

0

참고문헌

키워드

초록

Purpose: In this study, the relationship between the BRAFV600E mutation and the clinicopathological features of papillary thyroid microcarcinoma (PTMC) was examined in a single center. Methods: From January 2011 to December 2012, a total of 911 patients with PTMC who underwent thyroidectomy at Severance Hospital, Korea were enrolled in this study. The status of BRAFV600E mutation was assessed in thyroid fine-needle aspiration specimens by real-time polymerase chain reaction amplification prior to thyroidectomy. The associations between BRAFV600E mutation status and clinicopathological features of PTMC were examined. Results: The overall prevalence of the BRAFV600E mutations was 78.8% (717/911). Chi-square analysis revealed that BRAFV600E mutations were significantly associated with the male sex, lateral neck node metastasis, and several risk factors. And the age, tumor size, extent of surgery, multiplicity, bilaterality, central node metastasis, and distant metastasis were not associated with BRAFV600E mutation. Multivariate analysis showed that capsular invasion and lateral neck node metastasis were significantly associated with BRAFV600E mutations. In particular, lateral neck node metastasis showed negative correlation with BRAFV600E mutations. And the recurrence rate and disease-free survival were not associated with BRAFV600E mutation status. Conclusion: BRAFV600E mutations in PTMC was associated with presence of capsular invasion and absence of lateral neck node metastasis. However, BRAFV600E mutations could not serve as a prognostic factor that affected the recurrence of PTMC in our study.

Abstract

Purpose: In this study, the relationship between the BRAFV600E mutation and the clinicopathological features of papillary thyroid microcarcinoma (PTMC) was examined in a single center. Methods: From January 2011 to December 2012, a total of 911 patients with PTMC who underwent thyroidectomy at Severance Hospital, Korea were enrolled in this study. The status of BRAFV600E mutation was assessed in thyroid fine-needle aspiration specimens by real-time polymerase chain reaction amplification prior to thyroidectomy. The associations between BRAFV600E mutation status and clinicopathological features of PTMC were examined. Results: The overall prevalence of the BRAFV600E mutations was 78.8% (717/911). Chi-square analysis revealed that BRAFV600E mutations were significantly associated with the male sex, lateral neck node metastasis, and several risk factors. And the age, tumor size, extent of surgery, multiplicity, bilaterality, central node metastasis, and distant metastasis were not associated with BRAFV600E mutation. Multivariate analysis showed that capsular invasion and lateral neck node metastasis were significantly associated with BRAFV600E mutations. In particular, lateral neck node metastasis showed negative correlation with BRAFV600E mutations. And the recurrence rate and disease-free survival were not associated with BRAFV600E mutation status. Conclusion: BRAFV600E mutations in PTMC was associated with presence of capsular invasion and absence of lateral neck node metastasis. However, BRAFV600E mutations could not serve as a prognostic factor that affected the recurrence of PTMC in our study.

참고문헌 (33)

  1. DeLellis RA, "Pathology and Genetics of Tumours of Endocrine Organs" (2004), International Agency for Research on Cancer (IARC)
  2. Roti E, "Thyroid papillary microcarcinoma : a descriptive and meta-analysis study", Eur J Endocrinol, 159, pp.659~673 (2008)
  3. Haugen BR, "2015 American Thyroid Association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer : the American Thyroid Association guidelines task force on thyroid nodules and differentiated thyroid cancer", Thyroid, 26, pp.1~133 (2016)
  4. Davies H, "Mutations of the BRAF gene in human cancer", Nature, 417, pp.949~954 (2002)
  5. 송영신, "Mutation Profile of Well-Differentiated Thyroid Cancer in Asians", Endocrinology and Metabolism, 30(3), pp.252~262 (2015), 대한내분비학회
  6. Xing M., "BRAF mutation in papillary thyroid cancer: pathogenic role, molecular bases, and clinical implications", Endocr Rev, 28, pp.742~762 (2007)
  7. Mathur A, "A prospective study evaluating the accuracy of using combined clinical factors and candidate diagnostic markers to refine the accuracy of thyroid fine needle aspiration biopsy", Surgery, 148, pp.1170~1176 (2010)
  8. Xing M, "BRAF mutation and thyroid cancer recurrence", J Clin Oncol, 33, pp.2482~2483 (2015)
  9. Xing M, "Association between BRAF V600E mutation and recurrence of papillary thyroid cancer", J Clin Oncol, 33, pp.42~50 (2015)
  10. Kim SJ, "BRAF V600E mutation is associated with tumor aggressiveness in papillary thyroid cancer", World J Surg, 36, pp.310~317 (2012)
  11. Kwak JY, "Association of BRAFV600E mutation with poor clinical prognostic factors and US features in Korean patients with papillary thyroid microcarcinoma", Radiology, 253, pp.854~860 (2009)
  12. Choi SY, "The relationship between the BRAF(V600E)mutation in papillary thyroid microcarcinoma and clinicopathologic factors", World J Surg Oncol, 11, pp.291~ (2013)
  13. Li J, "The BRAF V600E mutation predicts poor survival outcome in patients with papillary thyroid carcinoma : a meta analysis", Int J Clin Exp Med, 8, pp.22246~22253 (2015)
  14. Annual report of cancer statistics in Korea in 2016, "Korea Central Cancer Registry, National Cancer Control Institute", Ministry of Health and Welfare, ~ (2018)
  15. Ahn HS, "Korea's thyroid-cancer"epidemic"--screening and overdiagnosis", N Engl J Med, 371, pp.1765~1767 (2014)
  16. Kim TY, "The BRAF mutation is not associated with poor prognostic factors in Korean patients with conventional papillary thyroid microcarcinoma", Clin Endocrinol(Oxf), 63, pp.588~593 (2005)
  17. Sun Y, "Correlation between the BRAF(v600E)gene mutation and factors influencing the prognosis of papillary thyroid microcarcinoma", Int J Clin Exp Med, 8, pp.22525~22528 (2015)
  18. Ito Y, "BRAF mutation in papillary thyroid carcinoma in a Japanese population : its lack of correlation with high-risk clinicopathological features and disease-free survival of patients", Endocr J, 56, pp.89~97 (2009)
  19. Goutas N, "BRAF and K-RAS mutation in a Greek papillary and medullary thyroid carcinoma cohort", Anticancer Res, 28, pp.305~308 (2008)
  20. Xing M, "BRAF V600E mutation and papillary thyroid cancer", JAMA, 310, pp.535~ (2013)
  21. Kim SK, "Clinical and pathological features and the BRAF(V600E)mutation in patients with papillary thyroid carcinoma with and without concurrent Hashimoto thyroiditis", Thyroid, 19, pp.137~141 (2009)
  22. Guan H, "Association of high iodine intake with the T1799A BRAF mutation in papillary thyroid cancer", J Clin Endocrinol Metab, 94, pp.1612~1617 (2009)
  23. 홍아람, "The Frequency and Clinical Implications of the BRAFV600E Mutation in Papillary Thyroid Cancer Patients in Korea Over the Past Two Decades", Endocrinology and Metabolism, 29(4), pp.505~513 (2014), 대한내분비학회
  24. Jung CK, "The increase in thyroid cancer incidence during the last four decades is accompanied by a high frequency of BRAF mutations and a sharp increase in RAS mutations", J Clin Endocrinol Metab, 99, pp.E276~E285 (2014)
  25. Liu C, "Reevaluating the prognostic significance of male gender for papillary thyroid carcinoma and microcarcinoma : a SEER database analysis", Sci Rep, 7, pp.11412~ (2017)
  26. Kim MJ, "Current trends in the features of male thyroid cancer: retrospective evaluation of their prognostic value", Medicine (Baltimore), 98, pp.e15559~ (2019)
  27. Pacini F., "Management of papillary thyroid microcarcinoma: primum non nocere!", J Clin Endocrinol Metab, 98, pp.1391~1393 (2013)
  28. Kwak JY, "Papillary microcarcinoma of the thyroid : predicting factors of lateral neck node metastasis", Ann Surg Oncol, 16, pp.1348~1355 (2009)
  29. Wu X, "Predicting factors of lateral neck lymph node metastases in patients with papillary thyroid microcarcinoma", Medicine (Baltimore), 98, pp.e16386~ (2019)
  30. Kim SK, "Role of BRAF V600E mutation as an indicator of the extent of thyroidectomy and lymph node dissection in conventional papillary thyroid carcinoma", Surgery, 158, pp.1500~1511 (2015)
  31. Moon HJ, "BRAF mutation in fine-needle aspiration specimens as a potential predictor for persistence", recurrence in patients with classical papillary thyroid carcinoma larger than 10 mm at a BRAF mutation prevalent area, 2015, pp.37, 1432~1438
  32. Ma YJ, "BRAF(V600E)mutation and its association with clinicopathological features of papillary thyroid microcarcinoma : a meta-analysis", J Huazhong Univ Sci Technolog Med Sci, 35, pp.591~599 (2015)
  33. Chung KW, "Detection of BRAFV600E mutation on fine needle aspiration specimens of thyroid nodule refines cyto-pathology diagnosis, especially in BRAF600E mutation-prevalent area", Clin Endocrinol(Oxf), 65, pp.660~666 (2006)

관련 논문AI추천

Null Association between BRAF V600E Mutation and Tumor Recurrence in Patients with Papillary Thyroid Microcarcinoma in South Korea김경진, 김남훈, 김신곤, 김주형, 김지윤, 김훈엽, 김희영, 배재현, 백승국, 정광윤대한갑상선학회 · International Journal of Thyroidology2021 · 제14권 제2호The Clinical Significance of the BRAF Mutation in Patients with Papillary Thyroid Cancer김수정, 소의영, 이정훈대한내분비외과학회 · Journal of Endocrine Surgery2017 · 제17권 제4호갑상선 유두암의 예후 예측 인자로서 BRAFV600E 돌연변이의 역할강진구, 권택주, 김완욱, 박지영, 박호용, 백진오, 이지연, 정지윤, 정진향, 황승욱대한내분비외과학회 · Journal of Endocrine Surgery2014 · 제14권 제3호갑상선 유두암에서 BRAFV600E 돌연변이와 연관된 임상병리학적 인자 및 초음파 소견과의 연관성강성준, 김광민, 박준범, 배금석, 최향숙대한내분비외과학회 · Journal of Endocrine Surgery2012 · 제12권 제1호초미세 갑상샘 유두암종에서의 BRAF 돌연변이 검출강소영, 권지은, 김태은, 노지현, 박희정, 오영륜, 최윤라대한병리학회 · Journal of Pathology and Translational Medicine2010 · 제44권 제3호Predicting Extrathyroidal Extension in Patients With Papillary Thyroid Microcarcinoma According to a BRAF Mutation김신곤, 백승국, 손규리, 안주현, 이도영, 정광윤, 채양석, 황수민대한이비인후과학회 · Clinical and Experimental Otorhinolaryngology2017 · 제10권 제2호

이 간행물의 다른 논문 (5건)